Back to Top

CML

0 comments

Submitted by Annemieke DeMaggio on Wed, 08/26/2020 - 10:05

BCR-ABL inhibitor asciminib (ABL001) meets phase 3 primary endpoint in CML

Asciminib significantly improved the Molecular Response Rate at 24 wks vs bosutinib in previously treated CML (Novartis press release)